The UDI Is on the Device. If Nobody Captures It at the Point of Care, Much of the Value Disappears.
TGA publishes new guidance for hospitals implementing UDI across inventory, clinical systems, patient records and recalls.
TGA publishes new guidance for hospitals implementing UDI across inventory, clinical systems, patient records and recalls.
Baxter recalls two saline lots for potential fiberglass particulate contamination, raising injectable particulate-control questions
FDA warns that GE Portrait software updates can remove monitored patients and reset alarm settings, creating a clinical change-control risk.
FDA has proposed reclassifying digital breast tomosynthesis (DBT) systems from Class III to Class II. If finalized, the change would replace the current PMA framework for these systems with Class II special controls plus 510(k) premarket notification requirements. For manufacturers, this could materially change both new-product submissions and lifecycle-management strategy.…
Learn new requirements of FDA QMSR implementation: How to align with ISO 13485, bridge gaps in records/labeling, prepare for risk-based inspections, and avoid shutdown risks.
Learn how FDA’s QMSR draft guidance helps secure PMA/HDE approvals pre-2026 deadline, with compliance steps, inspection changes, and transition strategies from QSR to ISO 13485.
Learn how blockchain enables medical device registration and traceability under FDA UDI and EU MDR, ensuring compliance, counterfeit prevention, and efficient recalls. (148 characters)
Medtech regulation shifts: Learn how to navigate new FDA changes on wearables, CDS, AI tools, and QMS, and realign strategy, risk, and compliance frameworks.
Explore how medical device labeling, UDI, and EU/FDA regulations enhance safety, traceability, and compliance while guiding practical risk and quality management.
Learn how AI integration in real-world evidence demands high-quality data, robust governance, and regulatory compliance to ensure trustworthy, regulator-ready insights.